Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
OXGN's Cash to Debt is ranked higher than
95% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. OXGN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OXGN' s Cash to Debt Range Over the Past 10 Years
Min: 23.3  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
OXGN's Interest Coverage is ranked higher than
94% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. OXGN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OXGN' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: -11.98
M-Score: -3.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -49.12
OXGN's ROE (%) is ranked lower than
62% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. OXGN: -49.12 )
Ranked among companies with meaningful ROE (%) only.
OXGN' s ROE (%) Range Over the Past 10 Years
Min: -8738.97  Med: -109.01 Max: -30.93
Current: -49.12
-8738.97
-30.93
ROA (%) -46.54
OXGN's ROA (%) is ranked lower than
67% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. OXGN: -46.54 )
Ranked among companies with meaningful ROA (%) only.
OXGN' s ROA (%) Range Over the Past 10 Years
Min: -224.41  Med: -82.36 Max: -28.65
Current: -46.54
-224.41
-28.65
ROC (Joel Greenblatt) (%) -43203.03
OXGN's ROC (Joel Greenblatt) (%) is ranked lower than
96% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. OXGN: -43203.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OXGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -40841.79  Med: -17941.64 Max: -9529.79
Current: -43203.03
-40841.79
-9529.79
Revenue Growth (3Y)(%) -100.00
OXGN's Revenue Growth (3Y)(%) is ranked lower than
94% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. OXGN: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OXGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -92.20 Max: 348.5
Current: -100
0
348.5
EBITDA Growth (3Y)(%) -53.50
OXGN's EBITDA Growth (3Y)(%) is ranked lower than
94% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. OXGN: -53.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OXGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.2  Med: -11.30 Max: 9.1
Current: -53.5
-66.2
9.1
EPS Growth (3Y)(%) -53.80
OXGN's EPS Growth (3Y)(%) is ranked lower than
93% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. OXGN: -53.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OXGN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -67.4  Med: -7.90 Max: 18.2
Current: -53.8
-67.4
18.2
» OXGN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

OXGN Guru Trades in Q2 2015

Jim Simons 493,700 sh (+303.68%)
» More
Q3 2015

OXGN Guru Trades in Q3 2015

Jim Simons 662,900 sh (+34.27%)
» More
Q4 2015

OXGN Guru Trades in Q4 2015

Jim Simons 819,800 sh (+23.67%)
» More
Q1 2016

OXGN Guru Trades in Q1 2016

Jim Simons 919,100 sh (+12.11%)
» More
» Details

Insider Trades

Latest Guru Trades with OXGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCBB:PRGB, OSL:HBC, OTCPK:ANTB, NAS:EBIO, OTCPK:EMBT, OTCBB:SNGX » details
Traded in other countries:OXGP.Germany,
OxiGene Inc is a biopharmaceutical company. The Company is engaged in development of vascular disrupting agents (VDAs) for the treatment of cancer. It has two clinical stage product candidates that are developed in three potential oncology indications.

OxiGene Inc was incorporated in 1988 in the state of New York and reincorporated in 1992 in the state of Delaware. It is a biopharmaceutical company. The Company is engaged in the development of vascular disrupting agents that disable and destroy abnormal blood vessels, which provide solid tumors a means of growth and survival, and also are associated with visual impairment in a various ophthalmological diseases and conditions. The Company is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients. It has two VDA drug candidates currently being tested in clinical trials, fosbretabulin and OXi4503. The competitors are include Bionomics, Immune Pharmaceuticals, and MediciNova .

Ratios

vs
industry
vs
history
P/B 0.80
OXGN's P/B is ranked higher than
96% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. OXGN: 0.80 )
Ranked among companies with meaningful P/B only.
OXGN' s P/B Range Over the Past 10 Years
Min: 0.24  Med: 1.56 Max: 12.17
Current: 0.8
0.24
12.17
Current Ratio 11.95
OXGN's Current Ratio is ranked higher than
80% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. OXGN: 11.95 )
Ranked among companies with meaningful Current Ratio only.
OXGN' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 10.24 Max: 58.71
Current: 11.95
0.81
58.71
Quick Ratio 11.95
OXGN's Quick Ratio is ranked higher than
81% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. OXGN: 11.95 )
Ranked among companies with meaningful Quick Ratio only.
OXGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 10.24 Max: 58.71
Current: 11.95
0.81
58.71

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.81
OXGN's Price/Net Cash is ranked higher than
99% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. OXGN: 0.81 )
Ranked among companies with meaningful Price/Net Cash only.
OXGN' s Price/Net Cash Range Over the Past 10 Years
Min: 0.8  Med: 2.90 Max: 18.54
Current: 0.81
0.8
18.54
Price/Net Current Asset Value 0.77
OXGN's Price/Net Current Asset Value is ranked higher than
98% of the 783 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. OXGN: 0.77 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OXGN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.8  Med: 2.83 Max: 23.73
Current: 0.77
0.8
23.73
Price/Tangible Book 0.76
OXGN's Price/Tangible Book is ranked higher than
97% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. OXGN: 0.76 )
Ranked among companies with meaningful Price/Tangible Book only.
OXGN' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.8  Med: 2.79 Max: 18.18
Current: 0.76
0.8
18.18
Price/Projected FCF 0.96
OXGN's Price/Projected FCF is ranked higher than
94% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. OXGN: 0.96 )
Ranked among companies with meaningful Price/Projected FCF only.
OXGN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.95  Med: 2.33 Max: 5.03
Current: 0.96
0.95
5.03
Earnings Yield (Greenblatt) (%) 237.21
OXGN's Earnings Yield (Greenblatt) (%) is ranked higher than
98% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. OXGN: 237.21 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OXGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 41.6  Med: 241.85 Max: 71344.9
Current: 237.21
41.6
71344.9

More Statistics

EPS (TTM) $ -0.55
Beta1.40
Short Percentage of Float2.18%
52-Week Range $0.49 - 1.68
Shares Outstanding (Mil)26.54

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $)
EPS ($) -0.88 -0.92 -0.81
EPS without NRI ($) -0.88 -0.92 -0.81
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for OXGN

Headlines

Articles On GuruFocus.com
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 
OXiGENE Inc. Reports Operating Results (10-Q) May 14 2010 
OXiGENE Inc. Reports Operating Results (10-Q) Nov 10 2009 
OXiGENE Inc. Reports Operating Results (10-Q) Aug 13 2009 
OXiGENE Inc. Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
OXIGENE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 24 2016
OXiGENE Announces Results of Phase 2 Study of CA4P in Recurrent Ovarian Cancer Published in Journal... May 24 2016
6:31 am OXiGENE announces results of phase 2 study of CA4P in recurrent ovarian cancer published in... May 24 2016
OXiGENE Announces Results of Phase 2 Study of CA4P in Recurrent Ovarian Cancer Published in Journal... May 24 2016
Cynapsus Therapeutics Appoints Frederick Driscoll to Its Board of Directors May 20 2016
OXIGENE INC Financials May 17 2016
OXiGENE Reports First Quarter 2016 Financial Results May 09 2016
OXiGENE Reports First Quarter 2016 Financial Results May 09 2016
OXIGENE INC Files SEC form 10-Q, Quarterly Report May 06 2016
OXIGENE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 30 2016
OXiGENE Spikes 13% Following Receipt Of Fast Track Designation Mar 30 2016
Oxigene Receives Fast Track Designation From U.S. FDA for CA4P Mar 30 2016
Oxigene Receives Fast Track Designation From U.S. FDA for CA4P Mar 30 2016
OXiGENE Reports 2015 Financial Results Mar 28 2016
OXiGENE Reports 2015 Financial Results Mar 28 2016
OXIGENE INC Files SEC form 10-K, Annual Report Mar 25 2016
Oxigene's pancreatic cancer treatments granted orphan drug status in Europe Mar 25 2016
OXiGENE Receives European Orphan Drug Designation for CA4P to Treat Neuroendocrine Tumors Mar 25 2016
OXiGENE Receives European Orphan Drug Designation for CA4P to Treat Neuroendocrine Tumors Mar 25 2016
OXIGENE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Mar 24 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)